Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Tohen, M. Articles by Bowden, C. L. Search for Related Content PubMed Citation Articles by Tohen, M. Articles by Bowden, C. L. Bipolar Disorder Atypical Neuroleptics Related Article

Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With Olanzapine

OBJECTIVE: In a placebo-controlled, double-blind study, the authors investigated the efficacy and safety of olanzapine as monotherapy in relapse prevention in bipolar I disorder. METHOD: Patients achieving symptomatic remission from a manic or mixed episode of bipolar I disorder (Young Mania Rating Scale [YMRS] total score 12 and 21-item Hamilton Depression Rating Scale [HAM-D] score 8) at two consecutive weekly visits following 6–12 weeks of open-label acute treatment with 5–20 mg/day of olanzapine were randomly assigned to double-blind maintenance treatment with olanzapine (N=225) or placebo (N=136) for up to 48 weeks. The primary measure of efficacy was time to symptomatic relapse into any mood episode (YMRS score 15, HAM-D score 15, or hospitalization). RESULTS: Time to symptomatic relapse into any mood episode was significantly longer among patients receiving olanzapine (a median of 174 days, compared with a median of 22 days in patients receiving placebo). Times to symptomatic relapse into manic, depressive, and mixed episodes were all significantly longer among patients receiving olanzapine than among patients receiving placebo. The relapse rate was significantly lower in the olanzapine group (46.7%) than in the placebo group (80.1%). During olanzapine treatment, the most common emergent event was weight gain; during the open-label phase, patients who received olanzapine gained a mean of 3.1 kg (SD=3.4). In double-blind treatment, placebo patients lost a mean of 2.0 kg (SD=4.4) and patients who continued to take olanzapine gained an additional 1.0 kg (SD=5.2). CONCLUSIONS: Compared to placebo, olanzapine delays relapse into subsequent mood episodes in bipolar I disorder patients who responded to open-label acute treatment with olanzapine for a manic or mixed episode.

Related Article:

In This Issue
Am J Psychiatry 2006 163: A38. [Full Text] [PDF]

This article has been cited by other articles:

				M. Franks, K. Macritchie, T Mahmood, and A. Young Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study J Psychopharmacol, June 1, 2008; 22(4): 452 - 456. [Abstract] [PDF]

				J. E. Pina-Garza, P. Levisohn, K. Gucuyener, M. A. Mikati, C. R. Warnock, H. S. Conklin, and J. Messenheimer Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months Neurology, May 27, 2008; 70(22_Part_2): 2099 - 2108. [Abstract] [Full Text] [PDF]

				G. S. Sachs Bipolar Disorder Clinical Synthesis: Where Does the Evidence Lead? Focus, January 1, 2007; 5(1): 3 - 13. [Abstract] [Full Text] [PDF]

				R. M.A. Hirschfeld Comment on Guideline Watch: Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition Focus, January 1, 2007; 5(1): 33 - 33. [Full Text] [PDF]

				Bibliography BIPOLAR DISORDER Focus, January 1, 2007; 5(1): 40 - 43. [Full Text] [PDF]

				L. Citrome Maintenance treatment with olanzapine reduces relapse in people with bipolar I disorder who have responded to acute olanzapine treatment. Evid. Based Ment. Health, August 1, 2006; 9(3): 73 - 73. [Full Text] [PDF]

				S. N. Ghaemi, D. J. Hsu, M. E. Thase, S. R. Wisniewski, A. A. Nierenberg, S. Miyahara, and G. Sachs Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants Psychiatr Serv, May 1, 2006; 57(5): 660 - 665. [Abstract] [Full Text] [PDF]

				S. Dando and M. Tohen Olanzapine - relapse prevention following mania. J Psychopharmacol, March 1, 2006; 20(2 Suppl): 31 - 38. [Abstract] [PDF]

				J. S. E. Hellewell A review of the evidence for the use of antipsychotics in the maintenance treatment of bipolar disorders. J Psychopharmacol, March 1, 2006; 20(2 Suppl): 39 - 45. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us